OraMod continues the research conducted by the finished FP7-NeoMark project: NeoMark produced a set of prognostic bio-markers and a genetic bio-signature significant for reoccurrence of oral cavity tumors - a disease more and more frequent and with a very high mortality rate.
By adopting the results of the most advanced research in oncology and of technology developments in the fields of genomics, image diagnostics and biostatistical predictive models, the project experts will provide to clinicians a technology platform allowing the early identification of patients at highest risk of bad prognosis.
Analysing data
The platform will be able to analyse tens of thousands clinical, radiology and genomic data for each individual patient. It will be able to detect the patients at high risk for disease reoccurrence, for whom personalised and specific therapeutic approaches will be adopted.
Low-cost identification
An innovative in vitro diagnostic device based on a personalized "lab-on-chip", will allow fast and low-cost identification of genomic predictive markers.
The OraMod project will receive a funding of more than € 3 million throughout three years. It engages 8 partners from 5 European countries, among which:
- three university hospitals (VU medical center Amsterdam, Heinrich-Heine University Clinic Dusseldorf and the University of Parma with the University Hospital);
- two primary European research institutions (the Fraunhofer Institute for Computer Graphics IGD Darmstad Germany and the VTT Technology Center of Finland) and;
- three technology providers (Velti in Greece, OneToNet and STmicroelectronics in Italy).